Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB-DTNB-NK in Relapsed or Refractory Neuroblastoma
NCT07502287Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of EB-DTNB-NK in neuroblastoma, ganglioneuroblastoma (GNB), sponsored by Biotech Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
EB-DTNB-NK
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on NCT07502287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502287.